The FDA analysts also raised concerns about whether women with medical conditions that should preclude them from taking the pill, primarily breast cancer and undiagnosed vaginal bleeding, would avoid the product.
The study discovered that "the overall risk of retinal vascular occlusion in the vaccinated cohort was 2.19 times higher than that in the unvaccinated cohort at 2 years (95% Cl 2.00–2.39)."
